Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients.

Maria Rosaria De CagnaVincenza ColucciArcangelo Di MaggioNorma NotaristefanoFrancesca CianciottaKatia DanzaFrancesca SalvatoreAnna SantoniccoloSalvatore Giovanni LanzillottaMaria Antonietta PerniolaAnna Lisa MarangiLuigi Francesco Pio MorroneMarilina Tampoia

Published in: Clinical and experimental nephrology (2023)

For HD and RTx, there is great variability in the humoral response to anti-COVID-19 vaccination, with a stronger response in the HD group. The booster dose was ineffective at reinforcing the humoral and cellular immune response in most RTx patients hyporesponsive to the second dose.

Keyphrases

immune response
end stage renal disease
coronavirus disease
ejection fraction
newly diagnosed
chronic kidney disease
toll like receptor
dendritic cells
peritoneal dialysis
prognostic factors
patient reported outcomes
patient reported